

Birte Yding Glenthj

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8644273/birte-yding-glenthj-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 papers	2,876 citations	29 h-index	50 g-index
97 ext. papers	3,546 ext. citations	5.1 avg, IF	5.3 L-index

#	Paper	IF	Citations
94	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , 2021 , 51, 1570-1580	6.9	9
93	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients. <i>European Neuropsychopharmacology</i> , 2021 , 46, 83-92	1.2	0
92	Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. <i>Biological Psychiatry</i> , 2021 , 89, 278-287	7.9	11
91	Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed. <i>Brain and Behavior</i> , 2021 , 11, e01962	3.4	3
90	Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response. <i>Biological Psychiatry</i> , 2021 ,	7.9	3
89	Associations of neural processing of reward with posttraumatic stress disorder and secondary psychotic symptoms in trauma-affected refugees. <i>Høire Utbildning</i> , 2020 , 11, 1730091	5	5
88	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. <i>Psychiatry Research</i> , 2020 , 290, 112969	9.9	2
87	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2020 , 77, 190-200	14.5	14
86	Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2020 , 45, 649-655	8.7	1
85	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of H-MRS studies. <i>Schizophrenia Research</i> , 2020 , 215, 38-48	3.6	21
84	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020 , 5, 569-579	3.4	7
83	M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAÏVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT. <i>Schizophrenia Bulletin</i> , 2020 , 46, S190-S190	1.3	78
82	M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAÏVE SCHIZOPHRENIA PATIENTS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S191-S192	1.3	78
81	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. <i>European Psychiatry</i> , 2020 , 63, e83	6	3
80	Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms. <i>Psychiatry Research</i> , 2020 , 294, 113498	9.9	3
79	The relation between dopamine D receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients. <i>Psychological Medicine</i> , 2020 , 50, 220-228	6.9	12
78	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , 2019 , 9, 20	8.6	30

77	17.3 USING RASCH ANALYSIS TO IDENTIFY NEGATIVE SYMPTOM RESPONSE TRAJECTORIES IN FIRST-EPIISODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2019 , 45, S116-S116	1.3	78
76	Startle habituation, sensory, and sensorimotor gating in trauma-affected refugees with posttraumatic stress disorder. <i>Psychological Medicine</i> , 2019 , 49, 581-589	6.9	8
75	Validation of the Danish version of the brief negative symptom scale. <i>Nordic Journal of Psychiatry</i> , 2019 , 73, 425-432	2.3	10
74	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , 2019 , 5, 12	5.5	12
73	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019 , 29, 947-959	1.2	36
72	Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. <i>Psychological Medicine</i> , 2019 , 49, 2617-2625	6.9	5
71	Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a [H]-spectroscopy twin study. <i>Neuropsychopharmacology</i> , 2019 , 44, 581-589	8.7	21
70	Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients. <i>Psychoneuroendocrinology</i> , 2018 , 92, 72-80	5	17
69	Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence - A Danish nationwide study. <i>Schizophrenia Research</i> , 2018 , 199, 116-122	3.6	7
68	Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder. <i>Psychological Medicine</i> , 2018 , 48, 604-616	6.9	7
67	Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. <i>Biological Psychiatry</i> , 2018 , 83, 492-498	7.9	205
66	Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2018 , 9, 22	5	15
65	Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018 , 44, 1332-1340	1.3	13
64	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018 , 5, 797-807	23.3	100
63	Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 997-1006	5.8	8
62	Negative Symptoms and Reward Disturbances in Schizophrenia Before and After Antipsychotic Monotherapy. <i>Clinical EEG and Neuroscience</i> , 2018 , 49, 36-45	2.3	13
61	White matter maturation during 12 months in individuals at ultra-high-risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 137, 65-78	6.5	18
60	O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2018 , 44, S80-S80	1.3	78

59	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 82-90	2.4	35
58	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 136, 52-62	6.5	24
57	Two subgroups of antipsychotic-naïve, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. <i>Translational Psychiatry</i> , 2017 , 7, e1087	8.6	25
56	Is an Early Age at Illness Onset in Schizophrenia Associated With Increased Genetic Susceptibility? Analysis of Data From the Nationwide Danish Twin Register. <i>EBioMedicine</i> , 2017 , 18, 320-326	8.8	14
55	Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms. <i>Psychological Medicine</i> , 2017 , 47, 2689-2707	6.9	25
54	Selective attention and mismatch negativity in antipsychotic-naïve, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy. <i>Psychological Medicine</i> , 2017 , 47, 2155-2165 ¹⁰	6.9	10
53	Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD. <i>Psychological Medicine</i> , 2017 , 47, 377-388	6.9	19
52	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Authors' response. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 136, 526-527	6.5	
51	Auditory processing in autism spectrum disorder: Mismatch negativity deficits. <i>Autism Research</i> , 2017 , 10, 1857-1865	5.1	25
50	Testing a decades-old assumption: Are individuals with lower sensory gating indeed more easily distracted?. <i>Psychiatry Research</i> , 2017 , 255, 387-393	9.9	3
49	Extrastriatal dopamine D receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 539-549	3.8	4
48	Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. <i>BMC Psychiatry</i> , 2016 , 16, 348	4.2	14
47	Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. <i>JAMA Psychiatry</i> , 2016 , 73, 121-8	14.5	46
46	Frontal fasciculi and psychotic symptoms in antipsychotic-naïve patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. <i>Journal of Psychiatry and Neuroscience</i> , 2016 , 41, 133-41	4.5	40
45	Low frontal serotonin 2A receptor binding is a state marker for schizophrenia?. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1248-50	1.2	19
44	Systemic oxidative DNA and RNA damage are not increased during early phases of psychosis: A case control study. <i>Psychiatry Research</i> , 2016 , 241, 201-6	9.9	17
43	Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. <i>Psychiatry Research</i> , 2016 , 240, 163-169	9.9	26
42	Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. <i>Schizophrenia Bulletin</i> , 2015 , 41, 1143-52	1.3	26

41	Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. <i>Schizophrenia Bulletin</i> , 2015 , 41, 574-83	1.3	68
40	Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. <i>Schizophrenia Bulletin</i> , 2015 , 41, 584-96	1.3	28
39	The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. <i>Schizophrenia Bulletin</i> , 2015 , 41, 549-58	1.3	38
38	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 142-70	3.8	84
37	The promise of biological markers for treatment response in first-episode psychosis: a systematic review. <i>Schizophrenia Bulletin</i> , 2015 , 41, 559-73	1.3	65
36	Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory. <i>Autism Research</i> , 2015 , 8, 371-8	5.1	22
35	Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. <i>Travel Medicine and Infectious Disease</i> , 2015 , 13, 80-8	8.4	32
34	Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 19, pyv109	5.8	14
33	Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome. <i>European Journal of Human Genetics</i> , 2014 , 22, 1283-9	5.3	52
32	Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naïve first-episode schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 1729-36	5.8	15
31	Structural brain correlates of sensorimotor gating in antipsychotic-naïve men with first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2013 , 38, 34-42	4.5	24
30	Norquetiapine and depressive symptoms in initially antipsychotic-naïve first-episode schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 266-9	1.7	4
29	Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. <i>Biological Psychiatry</i> , 2012 , 71, 898-905	7.9	157
28	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012 , 10, 92	11.4	19
27	A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. <i>PLoS ONE</i> , 2012 , 7, e39498	3.7	101
26	Serotonin 2A receptor antagonists for treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1211-23	5.9	56
25	Common variants at VRK2 and TCF4 conferring risk of schizophrenia. <i>Human Molecular Genetics</i> , 2011 , 20, 4076-81	5.6	162
24	Progressive striatal and hippocampal volume loss in initially antipsychotic-naïve, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 69-82	5.8	63

23	Hippocampal and caudate volume reductions in antipsychotic-naïve first-episode schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2010 , 35, 95-104	4.5	88
22	Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia--gating of auditory-evoked potentials and prepulse inhibition. <i>Behavioural Brain Research</i> , 2010 , 213, 142-7	3.4	21
21	Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. <i>Psychopharmacology</i> , 2009 , 206, 631-40	4.7	46
20	Effect of an NCAM mimetic peptide FGL on impairment in spatial learning and memory after neonatal phencyclidine treatment in rats. <i>Behavioural Brain Research</i> , 2009 , 199, 288-97	3.4	27
19	Evaluation of a neurodevelopmental model of schizophrenia--early postnatal PCP treatment in attentional set-shifting. <i>Behavioural Brain Research</i> , 2008 , 190, 160-3	3.4	60
18	Decreased gene expression of neuropeptide Y and its receptors in hippocampal regions during ethanol withdrawal in rats. <i>Neuroscience Letters</i> , 2007 , 424, 160-4	3.3	13
17	Prepulse inhibition in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 1045-50	5.6	43
16	Gating of the vertex somatosensory and auditory evoked potential P50 and the correlation to skin conductance orienting response in healthy men. <i>Psychiatry Research</i> , 2001 , 101, 221-35	9.9	48
15	A mixed modality paradigm for recording somatosensory and auditory P50 gating. <i>Psychiatry Research</i> , 2001 , 105, 79-86	9.9	14
14	Information processing and attentional dysfunctions as vulnerability indicators in schizophrenia spectrum disorders. <i>World Journal of Biological Psychiatry</i> , 2000 , 1, 5-15	3.8	19
13	Proprioceptive evoked potentials in man: cerebral responses to changing weight loads on the hand. <i>Neuroscience Letters</i> , 2000 , 288, 111-4	3.3	10
12	Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1997 , 21, 23-46	5.5	45
11	Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia. <i>Brain Research</i> , 1993 , 619, 39-54	3.7	30
10	Effects of chronic discontinuous and continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756). <i>European Journal of Pharmacology</i> , 1993 , 242, 283-91	5.3	4
9	Electrical kindling of rats treated discontinuously or continuously with haloperidol. <i>European Journal of Pharmacology</i> , 1993 , 236, 401-9	5.3	5
8	Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function. <i>Psychopharmacology</i> , 1993 , 113, 157-66	4.7	18
7	Development of vacuous chewing movements in rats: role of housing environment. <i>Life Sciences</i> , 1991 , 48, 2137-40	6.8	11
6	Intermittent versus continuous neuroleptic treatment in a rat model. <i>European Journal of Pharmacology</i> , 1990 , 190, 275-86	5.3	29

5	Effect of a dopamine D-1 agonist in rats treated chronically with zuclopenthixol. <i>Life Sciences</i> , 1990 , 47, 1339-46	6.8	6
4	Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. <i>European Journal of Pharmacology</i> , 1989 , 164, 393-6	5.3	26
3	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open</i> ,	2.2	2
2	The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study. <i>Psychological Medicine</i> , 1-11	6.9	1
1	Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. <i>Nordic Journal of Psychiatry</i> , 1-6	2.3	